Abstract：
Cancer is a multifaceted disorder frequently linked to the dysregulation of several biological processes. The SLPI is a multifunctional protein involved in the modulation of immunological response and the inhibition of protease activities. SLPI acts as an inhibitor of proteases, exerts antibacterial properties, and suppresses the transcription of proinflammatory genes through the nuclear factor-kappa B (NF-κB) pathway. The role of this protein as a regulatory agent has been implicated in various types of cancer. Recent research has revealed that SLPI upregulation in cancer cells enhances the metastatic capacity of epithelial malignancies, indicating the deleterious effects of this protein. Furthermore, SLPI interacts intricately with other cancer-promoting factors, including matrix metalloproteinase-2 (MMP-2), MMP-9, the NF-κB and Akt pathways, and the p53-upregulated modulator of apoptosis (PUMA). This review provides an overview of the role of SLPI in cancer pathophysiology, emphasizing its expression in cancer cells and tissues, its potential as a prognostic biomarker, and its therapeutic promise as a target in cancer treatment. The mechanisms of SLPI action in cancer, including its anti-inflammatory effects, regulation of cell proliferation and angiogenesis, and modulation of the tumor microenvironment, have been investigated. The clinical implications of SLPI in cancer have been discussed, including its potential as a diagnostic and prognostic biomarker, its role in chemoresistance, and its therapeutic potential in several types of cancer, such as hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic cancer, head and neck squamous cell carcinoma (HNSCC), ovarian cancer (OvCa), prostate cancer (PC), gastric cancer (GC), breast cancer, and other cancers. In addition, we emphasized the significance of SLPI in cancer, which offers fresh perspectives on potential targets for cancer therapy.
摘要：
癌症是一种多方面的疾病，经常与几种生物过程的失调有关。SLPI是参与调节免疫应答和抑制蛋白酶活性的多功能蛋白。SLPI作为蛋白酶的抑制剂，发挥抗菌性能，并通过核因子-κB（NF-κB）途径抑制促炎基因的转录。该蛋白质作为调节剂的作用已与各种类型的癌症有关。最近的研究表明，SLPI在癌细胞中的上调增强了上皮恶性肿瘤的转移能力，表明这种蛋白质的有害作用。此外，SLPI与其他促癌因子相互作用错综复杂，包括基质金属蛋白酶-2（MMP-2），MMP-9，NF-κB和Akt通路，和p53上调的细胞凋亡调节剂（PUMA）。本文综述了SLPI在癌症病理生理学中的作用。强调其在癌细胞和组织中的表达，它作为预后生物标志物的潜力，以及它作为癌症治疗靶点的治疗前景。SLPI在癌症中的作用机制，包括它的抗炎作用,细胞增殖和血管生成的调节，和肿瘤微环境的调节，已被调查。已经讨论了SLPI在癌症中的临床意义，包括其作为诊断和预后生物标志物的潜力，它在化学抗性中的作用，以及它在几种癌症中的治疗潜力，如肝细胞癌（HCC），结直肠癌(CRC),胰腺癌,头颈部鳞状细胞癌（HNSCC），卵巢癌（OvCa），前列腺癌(PC),胃癌（GC），乳腺癌,和其他癌症。此外,我们强调了SLPI在癌症中的重要性，这为癌症治疗的潜在靶点提供了新的视角。
